Free Trial
NASDAQ:VACC

Vaccitech (VACC) Stock Price, News & Analysis

$2.15
-0.25 (-10.41%)
(As of 05/21/2024 ET)
Today's Range
$2.15
$2.33
50-Day Range
$2.15
$3.67
52-Week Range
$1.64
$5.10
Volume
3,600 shs
Average Volume
244,643 shs
Market Capitalization
$82.93 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.63

Vaccitech MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
254.4% Upside
$7.63 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($2.41) to ($2.74) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.14 out of 5 stars

Medical Sector

769th out of 920 stocks

Pharmaceutical Preparations Industry

349th out of 413 stocks

VACC stock logo

About Vaccitech Stock (NASDAQ:VACC)

Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. The company's therapeutic programs include VTP-300, which is in Phase 1/2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1/2a clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious and autoimmunity diseases, and cancers. The company's therapeutic programs include VTP-300, which is in Phase 2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1b/2 clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom.Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom.

VACC Stock Price History

VACC Stock News Headlines

Vaccitech (NASDAQ:VACC) Stock Price Up 0.4%
Barinthus Biotherapeutics plc (BRNS)
Barinthus Biotherapeutics Plc. - ADR
SIRI, EC and PBTS among pre-market losers
Morgan Stanley Downgrades Vaccitech
Vaccitech surges despite Morgan Stanley downgrade
See More Headlines
Receive VACC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vaccitech and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/12/2021
Today
5/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:VACC
Fax
N/A
Employees
33
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$7.63
High Stock Price Target
$12.00
Low Stock Price Target
$3.25
Potential Upside/Downside
+254.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$5.34 million
Net Margins
-409.18%
Pretax Margin
-442.00%

Debt

Sales & Book Value

Annual Sales
$13.42 million
Cash Flow
$0.11 per share
Book Value
$6.52 per share

Miscellaneous

Free Float
36,234,000
Market Cap
$82.93 million
Optionable
Not Optionable
Beta
-0.40
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Mr. William J. Enright MBA (Age 60)
    CEO & Director
    Comp: $916.62k
  • Ms. Sarah Gilbert
    Co-Founder
  • Mr. Adrian Hill Ph.D.
    Co-Founder & Scientific Advisor
  • Ms. Gemma Brown (Age 33)
    CFO & Company Secretary
  • Mr. Chris Ellis (Age 63)
    Chief Operating Officer
  • Dr. Nadege Pelletier Ph.D. (Age 45)
    Chief Scientific Officer
  • Mr. Graham GriffithsMr. Graham Griffiths (Age 44)
    Chief Business Officer
  • Ms. Elizabeth Eagling-Vose M.B.A.
    Head of Clinical Operations
  • Bernie McDonald
    Head of IP
  • Geoffrey Lynn
    Senior Vice President of Synthetic Immunotherapies

VACC Stock Analysis - Frequently Asked Questions

Should I buy or sell Vaccitech stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Vaccitech in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" VACC shares.
View VACC analyst ratings
or view top-rated stocks.

What is Vaccitech's stock price target for 2024?

2 Wall Street analysts have issued 12 month target prices for Vaccitech's shares. Their VACC share price targets range from $3.25 to $12.00. On average, they anticipate the company's share price to reach $7.63 in the next year. This suggests a possible upside of 254.4% from the stock's current price.
View analysts price targets for VACC
or view top-rated stocks among Wall Street analysts.

How have VACC shares performed in 2024?

Vaccitech's stock was trading at $3.69 on January 1st, 2024. Since then, VACC stock has decreased by 41.7% and is now trading at $2.1513.
View the best growth stocks for 2024 here
.

How were Vaccitech's earnings last quarter?

Vaccitech plc (NASDAQ:VACC) announced its quarterly earnings results on Friday, November, 12th. The company reported ($0.13) EPS for the quarter, topping analysts' consensus estimates of ($0.38) by $0.25. The firm had revenue of $0.02 million for the quarter, compared to the consensus estimate of $1.65 million. Vaccitech had a negative trailing twelve-month return on equity of 23.41% and a negative net margin of 409.18%.

When did Vaccitech IPO?

Vaccitech (VACC) raised $110 million in an initial public offering (IPO) on Friday, April 30th 2021. The company issued 6,500,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, Jefferies, Barclays and William Blair acted as the underwriters for the IPO and H.C. Wainwright & Co., LLC was co-manager.

Who are Vaccitech's major shareholders?

Vaccitech's stock is owned by many different retail and institutional investors. Top institutional shareholders include M&G Plc (13.48%). Insiders that own company stock include Christopher Ellis, Graham Griffiths, Joseph Scheeren, Robin Wright and William Enright.
View institutional ownership trends
.

How do I buy shares of Vaccitech?

Shares of VACC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:VACC) was last updated on 5/21/2024 by MarketBeat.com Staff

From Our Partners